Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

2021/04/21 by Álvaro González‐Cantero, Alvaro González-Cantero, ­Daniel ­Ortega‐Quijano +17 · 17 citations
Immunology and Microbiology · Medicine · #Psoriasis: Treatment and Pathogenesis #Spondyloarthritis Studies and Treatments #Sarcoidosis and Beryllium Toxicity Research

paper · pdf · doi:10.1016/j.jid.2021.03.024

Cited by

• Trials and tribulations of systemic inflammation and cardiovascular risk in psoriasis
• L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines. [europepmc]
• IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis. [europepmc]
• Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk? [europepmc]
• Endothelial Dysfunction in Psoriasis: An Updated Review. [europepmc]
• Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial. [europepmc]
• Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics. [europepmc]
• Association of Biologic Treatment in Hidradenitis Suppurativa With Reduced Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio. [europepmc]
• The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review. [europepmc]
• Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study. [europepmc]
• Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data. [europepmc]
• Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis. [europepmc]
• Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. [europepmc]
• Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review. [europepmc]
• Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events. [europepmc]
• Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study. [europepmc]
• Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse. [europepmc]